GlassScriptPhysician profile
Teodora Kurteva
NPI 1891079232
$2,867.11
in general payments reported to CMS, 2019-2025
22 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $21.91 · 2021: $31.80 · 2022: $270 · 2023: $488 · 2024: $407 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595 · Travel and Lodging: $24.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.48 |
| Travel and Lodging | $24.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $814.62 | 2019-2023 | Spaceoar Vue System - 10ml |
| Abbvie INC. | $785.97 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $362.87 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $156.05 | 2019-2024 | Xtandi |
| Janssen Biotech, INC. | $121.96 | 2022-2025 | Erleada |
| Angiodynamics, INC. | $107.26 | 2023 | Nanoknife |
| Medtronic, INC. | $78.36 | 2025 | Altaviva, Interstim |
| Antares Pharma, INC. | $72.72 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Neotract INC. | $48.85 | 2019 | |
| Karl Storz Endoscopy-America | $40.01 | 2023 | |
| Allergan, INC. | $31.23 | 2021-2022 | |
| Blue Earth Diagnostics | $31.01 | 2025 | Posluma |
| Urogen Pharma, INC. | $30.43 | 2025 | |
| Myriad Genetic Laboratories, INC. | $30.14 | 2024 | Prolaris |
| Sumitomo Pharma America, INC. | $25.98 | 2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Metuchen Pharmaceuticals | $22.86 | 2019 | |
| Accord Healthcare, INC. | $22.10 | 2025 | |
| Endo Pharmaceuticals INC. | $20.51 | 2023 | Xiaflex |
| Tolmar, INC. | $18.76 | 2023 | |
| Halozyme INC | $16.49 | 2023 | |
| Merck Sharp & Dohme LLC | $16.14 | 2023 | Keytruda, Lynparza |
| Urovant Sciences INC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teodora Kurteva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.